IAVI Report

Linda-Gail Bekker talks about how she came to work on HIV and shares her thoughts on an evolving field.

Paul Stoffels of Johnson & Johnson talks about the company’s broad HIV portfolio and the role of industry in advancing vaccine research.

Although challenges remain, the growing field of mRNA-based vaccine development seems to have a bright future, with potential for preventing cancer, flu, and HIV.

More HIV-infected people than ever before are receiving life-saving treatment. Despite this progress, HIV incidence rates remain virtually static.

We must continue to engage local investigators and develop their capacity to conduct more basic and clinical research on the African continent.

Remembering Bonnie Mathieson: A champion of young scientists

The battle against HIV/AIDS lost another great soldier recently with the passing of Australian immunologist and clinician David Cooper on March 18. Cooper was a pioneering scientist and champion for HIV treatment and prevention, and he left an indelible mark on the field he dedicated his career to. “He had a great skill in knowing…

Jonathan Quick describes how the right mix of science, funding, leadership, and communication can come together to secure the world against future epidemics.

Influenza, like HIV, is a highly variable menace. A particularly bad flu season has researchers seeking ways to make a better vaccine, and in doing so, there may be lessons from, and for, HIV vaccine research.

Several areas of progress in using antibodies for HIV prevention were showcased at the recent Keystone Symposia.

We are at a defining moment in the history of HIV vaccine research. It is not an exaggeration to also propose that, thanks to the fruits of decades of HIV vaccine research and development efforts, we are entering a new era of vaccinology more broadly. A new generation of HIV vaccine candidates is poised to…

Coalition awards US$174 million in grants for research targeting Nipah virus, Lassa fever, and MERS.